Apogee Therapeutics, Inc.
APGE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Operating Activities | – | – | – |
| Net Income | -$182,146 | -$83,985 | -$39,785 |
| Dep. & Amort. | $189 | $0 | $0 |
| Deferred Tax | $0 | $0 | $0 |
| Stock-Based Comp. | $23,332 | $6,103 | $2,142 |
| Change in WC | -$2,002 | $6,105 | $9,815 |
| Other Non-Cash | -$10,547 | -$2,984 | $11,401 |
| Operating Cash Flow | -$171,174 | -$74,761 | -$16,427 |
| Investing Activities | – | – | – |
| PP&E Inv. | -$1,152 | -$167 | $0 |
| Net Acquisitions | $0 | $0 | $0 |
| Inv. Purchases | -$649,450 | -$303,743 | $0 |
| Inv. Sales/Matur. | $350,140 | $30,000 | $0 |
| Other Inv. Act. | $0 | $0 | $0 |
| Investing Cash Flow | -$300,462 | -$273,910 | $0 |
| Financing Activities | – | – | – |
| Debt Repay. | $0 | $0 | $0 |
| Stock Issued | $493,483 | $315,391 | $168,317 |
| Stock Repurch. | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 |
| Other Fin. Act. | $1,626 | $0 | $0 |
| Financing Cash Flow | $495,109 | $315,391 | $168,317 |
| Forex Effect | $0 | $0 | $0 |
| Net Chg. in Cash | $23,473 | -$33,280 | $151,890 |
| Supplemental Information | – | – | – |
| Beg. Cash | $118,610 | $151,890 | $0 |
| End Cash | $142,083 | $118,610 | $151,890 |
| Free Cash Flow | -$172,326 | -$74,928 | -$16,427 |